Exploring rituximab for the treatment of refractory myasthenia gravis: a single-centre experience.

BMJ Neurol Open · 2025 · PMC12684154 · PMID 41368039

Europe PMC DOI

hedged sentence

0.1730

closest p · 3.5× alpha

0.1730

boldest claim

The sentences

did not reach statistical significancep=0.173not close (p > 0.1)

Although the MG-QoL score improved from 30 (IQR 22–42) to 23 (IQR 15–33), 6 months after rituximab infusion, this change did not reach statistical significance (p=0.173), reflecting inter-individual variability in self-perceived outcomes.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.